Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is … Read more
Trevi Therapeutics Inc (TRVI) - Total Liabilities
Latest total liabilities as of September 2025: $9.57 Million USD
Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has total liabilities worth $9.57 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Trevi Therapeutics Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Trevi Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Trevi Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Trevi Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Air France-KLM SA
PINK:AFRAF
|
USA | $37.97 Billion |
|
Genius Sports Ltd
NYSE:GENI
|
USA | $405.81 Million |
|
Yellow Cake plc
OTCQX:YLLXF
|
USA | $3.40 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥1.55 Billion |
|
Bomin Electronics Co Ltd
SHG:603936
|
China | CN¥5.55 Billion |
|
Lendlease Global Commercial REIT
PINK:LLGCF
|
USA | $1.62 Billion |
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
USA | $852.47 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Trevi Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Trevi Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Trevi Therapeutics Inc (2016–2024)
The table below shows the annual total liabilities of Trevi Therapeutics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.26 Million | +64.18% |
| 2023-12-31 | $6.86 Million | -55.93% |
| 2022-12-31 | $15.56 Million | -27.31% |
| 2021-12-31 | $21.40 Million | +7.81% |
| 2020-12-31 | $19.85 Million | +263.80% |
| 2019-12-31 | $5.46 Million | +71.46% |
| 2018-12-31 | $3.18 Million | -57.29% |
| 2017-12-31 | $7.45 Million | -71.15% |
| 2016-12-31 | $25.82 Million | -- |